silybin has been researched along with atorvastatin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Dhanaraj, P; Israel, EVMV; Paulraj, MS; Sudha, N; Yousuf, S | 1 |
| Chen, S; Dong, Z; Liu, C; Zhang, W | 1 |
3 other study(ies) available for silybin and atorvastatin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
On the accessibility of surface-bound drugs on magnetic nanoparticles. Encapsulation of drugs loaded on modified dextran-coated superparamagnetic iron oxide by β-cyclodextrin.
Topics: Atorvastatin; beta-Cyclodextrins; Dextrans; Drug Compounding; Magnetite Nanoparticles; Magnetometry; Microscopy, Electron, Scanning; Pharmaceutical Preparations; Photoelectron Spectroscopy; Raloxifene Hydrochloride; Silybin; Silymarin; Spectrometry, Fluorescence; Surface Properties; X-Ray Diffraction | 2016 |
Silibinin A decreases statin‑induced PCSK9 expression in human hepatoblastoma HepG2 cells.
Topics: Atorvastatin; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatoblastoma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Promoter Regions, Genetic; Proprotein Convertase 9; RNA, Messenger; Silybin; Time Factors | 2019 |